Evidence map›Paper›PMID 31348884›Full record

ArticleCell2019

"Hey CIRI, What's My Prognosis?"

Jonathan C M Wan, James R White, Luis A Diaz

Abstract readComment
PubMed Publisher
In one paragraph

Article in Cell, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors.

Jonathan C M WanMemorial Sloan Kettering Cancer Center, New York, NY 10065, USA; School of Clinical Medicine, University of Cambridge, Cambridge CB2 0SP, UK.
James R WhiteMemorial Sloan Kettering Cancer Center, New York, NY 10065, USA; Resphera Biosciences, Baltimore, MD 21231, USA.
Luis A DiazMemorial Sloan Kettering Cancer Center, New York, NY 10065, USA. Electronic address: ldiaz@mskcc.org.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Although serial tumor assessments are increasingly performed through imaging and molecular approaches, such evaluations are often considered in isolation, as robust frameworks for integrating multiple biomarkers are currently lacking. Thus, in this issue of Cell, Kurtz et al. present a method (termed CIRI) that integrates pre-treatment and on-treatment risk factors for accurate outcome prediction.

Indexed as

Biomarkers, TumorRisk FactorsBiomarkers, Tumor

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.